Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01178 (
oxytocin
)
15,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Immunoreactive
oxytocin
(
OXT
) and arginine8-vasopressin (AVP) levels were measured in limbic areas of the mouse brain (hippocampus, amygdala and basal forebrain). Peptides were measured by radioimmunoassay (RIA). Acute morphine treatment caused a naloxone-reversible increase in
OXT
content in all three brain regions. The AVP contents of the same brain areas, on the other hand, were not affected by acute morphine treatment. In mice rendered tolerant to/dependent on morphine with subcutaneous morphine pellets, the
OXT
levels in the limbic brain structures were in the control range (basal forebrain and amygdala) or even decreased (hippocampus). In the latter brain structure of the tolerant animals, the AVP content was also decreased.
Naloxone
-precipitated withdrawal syndrome in the tolerant/dependent animals resulted in abrupt increases in the
OXT
and AVP levels of the hippocampus and in the
OXT
content of the basal forebrain structures.
...
PMID:Limbic oxytocin and arginine 8-vasopressin in morphine tolerance and dependence. 355 59
The effect of the opiate antagonist naloxone on neurohypophyseal hormone secretion has been investigated in rats given 2% NaCl to drink for 0-9 days.
Naloxone
elicited a rise in plasma levels of
oxytocin
(OT), but not arginine-vasopressin (AVP), on days 1-3 only, the greatest response being on day 2. In a further experiment, the OT response to an acute stimulus (1.5 M NaCl, i.p.) was found to be similar in controls and rats drinking 2% NaCl for 7 days, indicating that depletion of readily releasable hormone was not the cause of the loss of sensitivity to naloxone; rather a down-regulation of opiate receptor mechanisms may be responsible. The temporal changes in opiate antagonist-sensitivity in saline-loaded rats may provide a functional paradigm for the investigation of regulatory opiate mechanisms in neural tissue.
...
PMID:Temporal changes in the activity of endogenous opioid mechanisms regulating oxytocin secretion in saline-loaded rats. 369 93
Naloxone
, an opiate receptor antagonist, was used to determine whether opioid peptides modulate release of
oxytocin
(OT) or vasopressin (AVP) in the rat after expulsion of the fetus, i.e. parturition. We measured the concentrations of AVP and OT in plasma and in the neurointermediate lobe of the pituitary of pregnant rats given naloxone (5 mg/kg, s.c.) or saline on day 20 of gestation, and on day 21 either before or during the expulsive stage of labor. Non-pregnant rats in diestrus were given naloxone for comparison. On days 20 and 21 of gestation, before the onset of parturition, plasma [AVP] but not [OT] was elevated, compared to the non-pregnant controls. After delivery of the first two pups, plasma [OT] approximately doubled, whereas plasma [AVP] remained unchanged. Blocking the action of endogenous opioid peptides with naloxone caused an elevation of plasma [OT] in pregnant animals on days 20 and 21 of gestation and during parturition.
Naloxone
, however, did not alter plasma [AVP] in either parturient or preparturient animals. In contrast, [AVP], but not [OT], was increased in plasma of non-pregnant rats given naloxone. The content of OT in the neuro-intermediate lobe was similar in pregnant and non-pregnant rats and was unaffected by delivery of the first two pups. However, AVP content and the ratio of AVP/OT in the pituitary were lower in pregnant animals before and during delivery than in the non-pregnant controls. The content of neither hormone was altered by naloxone. Thus, AVP release apparently increases and pituitary stores of this peptide are decreased by day 20 of gestation, when labor has not yet begun.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Inhibition of release of neurohypophysial hormones by endogenous opioid peptides in pregnant and parturient rats. 375 22
Experiments were carried out to establish whether infusion of relaxin prolongs gestation and labour in the rat by suppressing release of
oxytocin
, and whether the effects of relaxin on birth could be reversed by the opioid antagonist naloxone. Female rats were implanted with subcutaneous osmotic minipumps for the infusion of purified porcine relaxin into the jugular vein for 84 h from either day 19 or day 20 of gestation. Infusion of relaxin delayed the onset of labour and in those animals which delivered during relaxin infusion, delivery was longer by approximately 45 min. Plasma
oxytocin
levels 40 min after delivery of the first fetus were 45.25 +/- 3.6 pmol/l (mean +/- S.D.) in unoperated controls and significantly (P less than 0.01) depressed (23.89 +/- 3.9) in rats that delivered during infusion of relaxin. Rats that delivered after the infusion of relaxin had finished, gave birth significantly (P less than 0.05) faster than controls and plasma
oxytocin
levels were significantly (P less than 0.01) raised (77.87 +/- 15.9 pmol/l).
Naloxone
treatment (1 mg/kg; i.m.) given immediately after the delivery of the first fetus reversed the inhibitory effect of relaxin and the interval between successive deliveries was slightly faster than that of controls. Plasma
oxytocin
levels in relaxin-infused naloxone-treated rats were significantly (P less than 0.01) higher than values in unoperated control rats. The results confirm that relaxin suppresses
oxytocin
release possibly through an opioid system and this may be important in the control of the timing of birth.
...
PMID:Relaxin acts centrally to inhibit oxytocin release during parturition: an effect that is reversed by naloxone. 378 86
The influence of endogenous opioids on the posterior pituitary response to stress was investigated by measuring plasma hormone levels in immobilized male and female rats following either acute naloxone treatment or prolonged morphine administration.
Naloxone
significantly potentiated the
oxytocin
and arginine vasopressin (AVP) response to immobilization, but in female rats only. The responses of morphine-treated male rats showed differences compared with vehicle-treated controls, although chronic morphine treatment did not reliably alter the
oxytocin
or AVP responses to immobilization in males or females. In a further experiment to investigate the role of gonadal hormones in determining the sex difference in responsiveness to naloxone, it was found that acute naloxone treatment significantly potentiated the posterior pituitary response to stress in castrated male rats. These results extend previous studies showing a sex difference in stress-induced secretion of posterior pituitary hormones, providing evidence of a sexual dimorphism in the endogenous opioid regulation of this response which is partly determined by circulating gonadal hormones.
...
PMID:A sex difference in endogenous opioid regulation of the posterior pituitary response to stress in the rat. 379 82
Endogenous opioid peptides inhibit secretion of
oxytocin
during dehydration, hemorrhage and parturition and attenuate release of vasopressin by tail electroshock. Diverse agents were used to stimulate the hypothalamo-neurohypophysial system to investigate the hypothesis that if
oxytocin
(or vasopressin) release were inhibited by opioid peptides regardless of the stimulus, the site of opiate action may be in the final common pathway (i.e. the magnocellular neuron) or on pituicytes in the neural lobe. Using male Sprague-Dawley rats, we therefore investigated the effect of an opiate receptor antagonist, naloxone (5 mg/kg s.c.), on the plasma concentrations of
oxytocin
and vasopressin elevated by various pharmacologic stimuli, including histamine (10 mg/kg i.p.), nicotine (0.15 or 1.5 mg/kg i.p.), isoproterenol (30 or 120 micrograms/kg i.m.) and increased [NaCl] in cerebrospinal fluid (CSF; 10 microliter artificial CSF containing 1 M NaCl i.v.t.). Control animals received saline (0.85%) or artificial CSF (containing 0.16 M NaCl). Animals were decapitated 60 s (increases[NaCl] in CSF) or 10 min after the stimulus or vehicle. Vasopressin and
oxytocin
were extracted from plasma and quantified by RIA. The concentrations of
oxytocin
and vasopressin in plasma were elevated (p less than 0.05) by histamine, isoproterenol (30 and 120 micrograms/kg), increases[NaCl] in CSF, and nicotine at the higher (1.5 mg/kg) but not lower (0.15 mg/kg) dose.
Naloxone
increased further (p less than 0.05) the concentration of
oxytocin
in plasma after histamine, nicotine (0.15 and 1.5 mg/kg), isoproterenol (30 and 120 micrograms/kg) and increases[NaCl] in CSF.
Naloxone
also increased (p less than 0.05)
oxytocin
concentration in controls receiving CSF or saline.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Naloxone effects on plasma vasopressin and oxytocin concentrations elevated by histamine, nicotine, isoproterenol and an acute increase in [NaCl] in cerebrospinal fluid. 379 91
Immobilization of adult male rats resulted in concomitant, significant releases of prolactin (PRL) and
oxytocin
(OT).
Naloxone
(0.2 mg/kg, i.p.) administration 30 min prior to initiation of restraint resulted in a significant diminution of the PRL response to stress. On the other hand, a significant augmentation of OT release was observed. These results demonstrate that concomitant releases of OT and PRL in response to a given physiologic stimulus (stress) can be dissociated and suggest that the hypothalamic events which are responsible for the release of these hormones during stress are different.
...
PMID:Naloxone-induced dissociation of oxytocin and prolactin releases. 396
The hypothalamo-neurohypophysial system is altered in the spontaneously hypertensive rat (SHR). We hypothesized that an aberrant regulation of vasopressin (VP) and
oxytocin
(OT) release by endogenous opioid peptides alters this neuroendocrine system in the SHR. Concentrations of the neurohypophysial hormones in plasma and the pituitary were measured in 17-week-old SHRs and two strains of normotensive controls. Wistar Kyoto (WKY) and Sprague-Dawley rats. Animals were decapitated 20 min after s.c. injection of saline (1 ml/kg) or naloxone hydrochloride (1 or 10 mg/kg). In addition, neurohypophysial hormones excreted during the day (08.00-17.30 h) and night (17.30-08.00 h) were determined in urine from 16-week-old animals kept in metabolic cages for 5 days. VP at extrahypothalamic sites was also measured as [VP] in acid extracts of the subfornical organ area, hippocampal commissure-fornix and choroid plexus. Hormones were quantified by radioimmunoassay. The pituitary content, plasma concentration, and urinary excretion of OT were reduced (P less than 0.05) in SHRs, whereas VP content was increased (P less than 0.05) in the pituitary and plasma, but unchanged in urine, of hypertensive animals. In extrahypothalamic tissues, [VP] in the hippocampal commissure-fornix was increased in the SHR.
Naloxone
elevated (P less than 0.05) the plasma concentration of OT in WKY animals and VP in SHRs. Neither [VP] nor [OT] in plasma was changed by naloxone in Sprague-Dawley rats. Pituitary stores of the neurohypophysial hormones were not altered by naloxone in either hypertensive or normotensive rats. In conclusion, endogenous opioid peptides tonically inhibit OT release in WKY rats, whereas VP release is decreased by opioid peptides in SHRs, 16-17 weeks of age. The neuromodulatory role of opioid peptides in the release of neurohypophysial hormones appears to be altered in the SHR such that VP release is suppressed and OT release is augmented.
...
PMID:Differential effects of naloxone on the release of neurohypophysial hormones in normotensive and spontaneously hypertensive rats. 397 14
Dynorphin (1-17), and to a lesser extent, beta-endorphin and [Leu]enkephalin (10(-6) M each) decreased the spontaneous release of vasopressin (VP) from the rat neurointermediate pituitary in vitro, whereas the
oxytocin
(OT) release remained unchanged.
Naloxone
, however, did not significantly alter the spontaneous VP and OT release. Dynorphin (1-17) (10(-7) M) increased the electrically evoked release of VP and OT, while 10(-6) M had a significant, somewhat less pronounced stimulatory effect only on VP, but not on OT release. The opiate inactive fragment [des-Tyr1]dynorphin (1-17) did not change the evoked VP and OT release, indicating that the dynorphin effect was mediated by opiate receptors. beta-Endorphin (10(-6) M and 10(-7) M) did not alter the evoked VP and OT secretion. 10(-6) M [Leu]enkephalin induced a stimulation of the evoked OT, but not VP release; 10(-7) M [Leu]enkephalin had no effect, neither on VP nor on OT release. The opiate antagonist naloxone (10(-5) M) induced an increase in the evoked VP and, even more pronounced, OT release. In a concentration of 10(-6) M, however, naloxone only increased the evoked OT release. When naloxone and dynorphin (1-17) were concomitantly applied, their stimulatory effects on the evoked VP and OT release were additive. Similarly to the effects of naloxone, addition of a monoclonal antibody which binds to the common N-terminal sequence of all endogenous opioid peptides, resulted in a marked increase in the evoked secretion of VP and, to an even more pronounced degree, of OT.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Differential effects of various opioid peptides on vasopressin and oxytocin release from the rat pituitary in vitro. 615 15
Morphine inhibits suckling-induced
oxytocin
(OT) release in lactating mice. Since beta-endorphin and enkephalins have several actions in common with morphine, the action of these opioid peptides on OT release was investigated. In anesthetized lactating rats, OT release was achieved by intraventricular injection of acetylcholine (ACh) or by the physiological stimulus of suckling. The amount of OT released was estimated by comparing milk-ejection responses to these stimuli to those following known amounts of intravenous (IV) OT. Both beta-endorphin and [D-Ala2]Met-enkephalin inhibited ACh-induced and suckling-induced OT release.
Naloxone
antagonized opiate inhibition in both cases.
...
PMID:Morphine, beta-endorphin and [D-Ala2] Met-enkephalin inhibit oxytocin release by acetylcholine and suckling. 629 Oct 11
<< Previous
1
2
3
4
5
6
7
Next >>